Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
SUM1315MO2 Neratinib
1.0
EGFR/HER2
RTK
 0.1748 0.08909
SUM1315MO2 Neratinib
3.1623
EGFR/HER2
RTK
 0.1140 0.08879
SUM1315MO2 Tivantinib
0.001
MET
RTK
 1.0417 0.00389
SUM1315MO2 Tivantinib
0.0031623
MET
RTK
 1.0192 -0.00120
SUM1315MO2 Tivantinib
0.01
MET
RTK
 1.0181 0.00453
SUM1315MO2 Tivantinib
0.031623
MET
RTK
 0.9355 0.00282
SUM1315MO2 Tivantinib
0.1
MET
RTK
 0.9251 0.03883
SUM1315MO2 Tivantinib
0.31623
MET
RTK
 0.6152 0.11278
SUM1315MO2 Tivantinib
1.0
MET
RTK
 -0.1924 0.42530
SUM1315MO2 Tivantinib
3.1623
MET
RTK
 -0.4277 0.44873
SUM1315MO2 Tivantinib
10.0
MET
RTK
 -0.4300 0.51069
SUM1315MO2 Cediranib
0.001
VEGFR/cKIT
RTK
 1.0030 0.00282
SUM1315MO2 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0254 -0.00232
SUM1315MO2 Cediranib
0.01
VEGFR/cKIT
RTK
 1.0347 0.00591
SUM1315MO2 Cediranib
0.031623
VEGFR/cKIT
RTK
 0.9914 0.00424
SUM1315MO2 Cediranib
0.1
VEGFR/cKIT
RTK
 0.9788 0.00298
SUM1315MO2 Cediranib
0.31623
VEGFR/cKIT
RTK
 0.7669 0.01075
SUM1315MO2 Cediranib
1.0
VEGFR/cKIT
RTK
 0.5716 0.02666
SUM1315MO2 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.2993 0.07623
SUM1315MO2 Cediranib
10.0
VEGFR/cKIT
RTK
 -0.2276 0.32283
SUM1315MO2 Cabozantinib
0.001
VEGFR2/MET
RTK
 1.0236 -0.00289
SUM1315MO2 Cabozantinib
0.0031623
VEGFR2/MET
RTK
 1.0576 0.00449
SUM1315MO2 Cabozantinib
0.01
VEGFR2/MET
RTK
 1.0048 0.00360
SUM1315MO2 Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.0767 0.00262
SUM1315MO2 Cabozantinib
0.1
VEGFR2/MET
RTK
 0.9699 0.00994